Virax Biolabs Group Ltd. Class A (VRAX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Virax Biolabs Group Ltd. Class A has reported an increase in total assets and stockholder equity as of September 30, 2024, compared to March 31, 2024. However, the company experienced a reduction in revenue and a net loss for the six months ending September 30, 2024, compared to the same period in 2023. Despite the financial challenges, the company’s non-current assets have shown growth, suggesting potential future opportunities.
For further insights into VRAX stock, check out TipRanks’ Stock Analysis page.
